You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

Oritavancin diphosphate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for oritavancin diphosphate and what is the scope of freedom to operate?

Oritavancin diphosphate is the generic ingredient in two branded drugs marketed by Melinta Therap and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has thirty-nine patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for oritavancin diphosphate
International Patents:39
US Patents:3
Tradenames:2
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 27
Clinical Trials: 4
Patent Applications: 54
What excipients (inactive ingredients) are in oritavancin diphosphate?oritavancin diphosphate excipients list
DailyMed Link:oritavancin diphosphate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oritavancin diphosphate
Generic Entry Dates for oritavancin diphosphate*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
Dosage:
POWDER;INTRAVENOUS
Generic Entry Dates for oritavancin diphosphate*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for oritavancin diphosphate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Melinta Therapeutics, Inc.Phase 2
The Medicines CompanyPhase 1

See all oritavancin diphosphate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for oritavancin diphosphate

US Patents and Regulatory Information for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 ⤷  Try a Trial ⤷  Try a Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for oritavancin diphosphate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2337575 2016/040 Ireland ⤷  Try a Trial PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319
2337575 132016000101430 Italy ⤷  Try a Trial PRODUCT NAME: ORITAVANCINA E I SUOI SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE IL DIFOSFATO(ORBACTIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/989, 20150323
2337575 1690041-7 Sweden ⤷  Try a Trial PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.